Patents by Inventor Alireza Rezaie

Alireza Rezaie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080058265
    Abstract: This invention relates to a novel form of protein C or activated protein C. More specifically, the invention is directed to a variant of protein C that is activated at a higher rate than wild-type or other variants and produces an activated protein C with reduced anticoagulant properties while retaining the protective anti-inflammatory and anti-apoptotic properties of wild-type activated protein C. This novel APC variant will be beneficial for treating inflammatory and apoptotic disorders with a reduced risk for bleeding.
    Type: Application
    Filed: August 30, 2007
    Publication date: March 6, 2008
    Inventors: Alireza Rezaie, Likui Yang
  • Patent number: 7247453
    Abstract: A Ca2+ dependent recombinant antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C has been constructed. The antibody does not bind to Activated Protein C and can be used to inhibit activation of Protein C by thrombin-thrombomodulin, in purification of Protein C, and in treatment of tumors.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: July 24, 2007
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Alireza Rezaie, Charles T. Esmon
  • Patent number: 6794493
    Abstract: Mutant antithrombin modified to carry a more positive charge in the H-helix is provided. The modified antithrombin modulates the activities of thrombin, and extends the bioavailability of factor VIII.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: September 21, 2004
    Assignee: WiSys Technology Foundation, Inc.
    Inventors: Timothy Walston, Scott Cooper, Alireza Rezaie
  • Publication number: 20010055591
    Abstract: Mutant antithrombin modified to carry a more positive charge in the H-helix is provided. The modified antithrombin modulates the activities of thrombin, and extends the bioavailability of factor VIII.
    Type: Application
    Filed: April 6, 2001
    Publication date: December 27, 2001
    Inventors: Timothy Walston, Scott Cooper, Alireza Rezaie
  • Patent number: 5298599
    Abstract: A method is disclosed to make any protein in a form that can be isolated rapidly from a solution using a specific monoclonal antibody designated "HPC-4". It has now been determined that it is possible to form a fusion protein of the epitope with a protein to be isolated, and isolate the protein using HPC-4-based affinity chromatography. In the preferred embodiment, a specific protease cleavage site is inserted between the epitope and the protein so that the epitope can be easily removed from the isolated protein. In an example, a functionally active soluble tissue factor including the twelve amino acid epitope recognized in combination with calcium by HPC-4 and a factor Xa cleavage site was expressed from a vector inserted into a procaryotic expression system. The recombinant tissue factor can be rapidly isolated in a single chromatographic step using the HPC-4 monoclonal antibody immobilized on a suitable substrate.
    Type: Grant
    Filed: January 3, 1992
    Date of Patent: March 29, 1994
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Alireza Rezaie, Charles T. Esmon, James H. Morrissey